Caribou Biosciences, Inc.
NASDAQ: CRBU0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Rachel E. Haurwitz
- Employees
- 147
- Headquarters
- Berkeley, United States
- IPO year
- 2021
- Market cap
- $164.6M
- Website
- https://cariboubio.com
Loading CRBU…
Loading profile data…Frequently asked questions about CRBU
What does Caribou Biosciences, Inc. (CRBU) do?
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary the...
Where does CRBU trade?
Caribou Biosciences, Inc. (CRBU) trades on the NASDAQ Global Select.
What sector is CRBU in?
Caribou Biosciences, Inc. (CRBU) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Caribou Biosciences, Inc.?
Rachel E. Haurwitz is the chief executive officer of Caribou Biosciences, Inc. (CRBU).
Where is Caribou Biosciences, Inc. headquartered?
Caribou Biosciences, Inc. is headquartered in United States.
Does CRBU pay a dividend?
Caribou Biosciences, Inc. (CRBU) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CRBU go public?
Caribou Biosciences, Inc. (CRBU) completed its initial public offering in 2021.